217 related articles for article (PubMed ID: 12007541)
21. Glucagon-like peptide-1: a potent regulator of food intake in humans.
Gutzwiller JP; Göke B; Drewe J; Hildebrand P; Ketterer S; Handschin D; Winterhalder R; Conen D; Beglinger C
Gut; 1999 Jan; 44(1):81-6. PubMed ID: 9862830
[TBL] [Abstract][Full Text] [Related]
22. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
[TBL] [Abstract][Full Text] [Related]
23. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats.
Donahey JC; van Dijk G; Woods SC; Seeley RJ
Brain Res; 1998 Jan; 779(1-2):75-83. PubMed ID: 9473596
[TBL] [Abstract][Full Text] [Related]
24. Role of GLP-1 in meal-taking.
Hellström PM; Näslund E
Appetite; 1999 Apr; 32(2):276. PubMed ID: 10097034
[No Abstract] [Full Text] [Related]
25. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
D'Alessio DA; Vahl TP
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
Nauck M
Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
[TBL] [Abstract][Full Text] [Related]
27. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling.
Scrocchi LA; Marshall BA; Cook SM; Brubaker PL; Drucker DJ
Diabetes; 1998 Apr; 47(4):632-9. PubMed ID: 9568697
[TBL] [Abstract][Full Text] [Related]
28. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man.
Long SJ; Sutton JA; Amaee WB; Giouvanoudi A; Spyrou NM; Rogers PJ; Morgan LM
Br J Nutr; 1999 Apr; 81(4):273-9. PubMed ID: 10999014
[TBL] [Abstract][Full Text] [Related]
29. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion.
MacDonald PE; El-Kholy W; Riedel MJ; Salapatek AM; Light PE; Wheeler MB
Diabetes; 2002 Dec; 51 Suppl 3():S434-42. PubMed ID: 12475787
[TBL] [Abstract][Full Text] [Related]
30. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
31. The potential role of glucagon-like peptide 1 in diabetes.
Meier JJ; Nauck MA
Curr Opin Investig Drugs; 2004 Apr; 5(4):402-10. PubMed ID: 15134281
[TBL] [Abstract][Full Text] [Related]
32. Glucagon-like peptide 1 (GLP-1) and eating.
Gutzwiller JP; Degen L; Heuss L; Beglinger C
Physiol Behav; 2004 Aug; 82(1):17-9. PubMed ID: 15234584
[TBL] [Abstract][Full Text] [Related]
33. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
Gefel D; Barg Y; Zimlichman R
Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
[TBL] [Abstract][Full Text] [Related]
34. Glucagon-like peptides.
Drucker DJ
Diabetes; 1998 Feb; 47(2):159-69. PubMed ID: 9519708
[TBL] [Abstract][Full Text] [Related]
35. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.
Egan JM; Bulotta A; Hui H; Perfetti R
Diabetes Metab Res Rev; 2003; 19(2):115-23. PubMed ID: 12673779
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic and extrapancreatic effects of GLP-1.
Valverde I; Villanueva-Peñacarrillo ML; Malaisse WJ
Diabetes Metab; 2002 Dec; 28(6 Pt 2):3S85-9; discussion 3S108-12. PubMed ID: 12688638
[TBL] [Abstract][Full Text] [Related]
37. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.
Drucker DJ
Mol Endocrinol; 2003 Feb; 17(2):161-71. PubMed ID: 12554744
[TBL] [Abstract][Full Text] [Related]
38. Overview of incretin hormones.
Efendic S; Portwood N
Horm Metab Res; 2004; 36(11-12):742-6. PubMed ID: 15655702
[TBL] [Abstract][Full Text] [Related]
39. A new Alzheimer's disease interventive strategy: GLP-1.
Perry TA; Greig NH
Curr Drug Targets; 2004 Aug; 5(6):565-71. PubMed ID: 15270203
[TBL] [Abstract][Full Text] [Related]
40. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
